A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson’s disease, according to results from a phase 1 clinical ...

Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Our Killer50 companies traditionally enjoy a strong start to a new year. In 2024, nine companies (six in the Life Sciences segment) raised a collective $711m. The big winners then were quantum ...